Physostigmine holds patents for treating dementia and Alzheimer’s disease as well as inhibiting butyrylcholinesterase, acetylcholinesterase inhibition, and memory enhancement. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.